DRKS00020237
Completed
Phase 3
Outcome after prolonged sedation - IsoOut-Study
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- J80.01
- Sponsor
- Sedana Medical AB
- Enrollment
- 301
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •IsoConDa Study plus
- •Ventilation for more than 96 hours
- •Inclusion criteria for the main study called A randomised, controlled, open\-label study to confirm the efficacy and safety of sedation with isoflurane in invasively ventilated ICU patients using the AnaConDa administration system
- •1\. Male or female subjects, \= 18 years (18 or older)
- •2\. Continuous invasive ventilation and sedation \= 48 hours (48 hours or less) at start of study sedation
- •3\. Clinically likely to need invasive ventilation and sedation \= 24 hours (24 hours or more) at randomisation
- •4\. Ongoing sedation with propofol at time of randomisation
- •5\. Prescribed target sedation depth within the RASS range \-1 to \-4
- •6\. Signed informed consent or emergency situation inclusion criteria fulfilled and documented.
Exclusion Criteria
- •IsoConDa Study
- •Exclusion criteria for the main study called A randomised, controlled, open\-label study to confirm the efficacy and safety of sedation with isoflurane in invasively ventilated ICU patients using the AnaConDa administration system
- •1\. Has not reached prescribed target sedation depth any time within the last 8 hours at randomisation
- •2\. History of or genetic predisposal for malignant hyperthermia
- •3\. Uncompensated acute circulatory failure at time of randomisation (MAP \< 55 mmHg despite iv fluids and vasopressors).
- •4\. Hepatic impairment of classification C according to the Child\-Pugh score (Cholongitas et al., 2005\).
- •5\. Any for the study, relevant clinically significant abnormalities in clinical chemistry or haematology results at the time of screening, precluding study participation, as judged by the investigator
- •6\. Acute neuropathology without ICP monitoring, including but not limited to stroke, neurosurgery and head trauma.
- •7\. Planned anaesthesia or surgery within 24 hours from randomisation
- •8\. Tidal volume \< 350 ml
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study of the influence of prolonged administration of topiroxostat and control of serum uric acid level on renal function in hyperuricemia patientsHyperuricemiaJPRN-UMIN000044642Medical corporation jyosuikai Shimada hospital Hidetaka Shimada75
Not yet recruiting
Phase 2
to compare the quality of pain relief with two drugs given in spinal anaesthesia forlower segmemt cesarean sectionHealth Condition 1: O82- Encounter for cesarean delivery without indicationCTRI/2020/08/027280SGRDIMSAR
Active, not recruiting
Not Applicable
Evaluation of the solvent Evaporation Time of universal adhesives in the quality of Cervical Lesions restorationsTooth AbrasionTooth AttritionTooth ErosionRBR-2hbf2mxniversidad de los Andes, Chile
Withdrawn
Not Applicable
A Study to Evaluate the Use of GALA (Trademark), a Preservation Solution for Blood Vessels in Patients Undergoing Coronary Artery Bypass Graft Surgery.ACTRN12613000707763Mobius Medical Pty Ltd25
Active, not recruiting
Phase 1
A Follow-Up Study of Long-Term Efficacy of Patients with HER2-Positive Early Breast Cancer Who Had Been Enrolled in Study CT-P6 3.2ong-term safety and efficacy of treatment with CT-P6 (Herzuma) in HER-2 positive early breast cancer patientsTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-003518-15-ROCelltrion, Inc.216